Injectable
Tirzepatideplus
A next-generation GLP-1 and GIP dual-receptor agonist co-formulated with glycine for advanced weight management.
- Once-weekly subcutaneous injection
- Dual GLP-1 and GIP receptor agonist for stronger metabolic effect
- Glycine adjunct supports muscle recovery and cellular repair
- Six vial sizes from 10 mg / 1 mL to 60 mg / 2 mL
About the ingredient
Tirzepatide + Glycine
Tirzepatide is a dual GIP/GLP-1 receptor agonist (incretin mimetic). Glycine is a non-essential amino acid that supports muscle protein synthesis and cellular recovery.
Tirzepatide + Glycine is a next-generation GLP-1 and GIP receptor agonist formulation created to deliver superior results in weight reduction and metabolic balance. This injectable combines Tirzepatide, a dual-action incretin mimetic that enhances both insulin and glucagon regulation, with Glycine, an amino acid that supports muscle recovery, cellular repair, and improved metabolic function.
Administered once weekly via subcutaneous injection, this formulation promotes powerful, sustained weight loss, enhances glucose control, and supports cardiovascular and overall metabolic health. The addition of Glycine optimizes cellular performance and recovery, amplifying Tirzepatide's metabolic benefits and helping patients achieve longer-lasting results.
Dual incretin action
By activating both GLP-1 and GIP receptors, tirzepatide delivers stronger appetite regulation and glucose control than single-receptor GLP-1 agonists.
Glycine adjunct
Glycine supports muscle protein synthesis and metabolic recovery, complementing tirzepatide during periods of caloric restriction.
Once-weekly maintenance
Long half-life supports once-weekly dosing with steady plasma levels and improved adherence vs. daily medications.
How to take
A consistent routine matters.
Follow the specific directions from your healthcare provider. These steps are a general reference for injectable administration.
- 1
Inspect the vial — solution should be clear and free of particles before each use.
- 2
Clean the vial stopper with a fresh alcohol swab and let it air-dry.
- 3
Draw the prescribed dose using an insulin syringe; tap out any air bubbles.
- 4
Inject subcutaneously into the abdomen, thigh, or upper arm, rotating sites each dose.
- 5
Discard the used syringe immediately in an FDA-cleared sharps container.
Product Details
Available formulations
| Vial | Vial Total mg | Concentration | mL |
|---|---|---|---|
 | 10 mg | 10 mg / 20 mg/mL | 1 mL |
 | 20 mg | 10 mg / 20 mg/mL | 2 mL |
 | 30 mg | 10 mg / 20 mg/mL | 3 mL |
 | 40 mg | 10 mg / 20 mg/mL | 4 mL |
 | 60 mg | 30 mg / 20 mg/mL | 2 mL |
Typical dosage & titration
Recommended titration schedule
Reference schedule only — your provider may adjust the timing or dose based on your individual response and lab work.
| Weeks | Units | MG | ML | SIG / Directions |
|---|---|---|---|---|
| 1–4 | 25 | 2.5 mg | 0.25 mL | Inject 25 units (2.5 mg) subcutaneously once weekly. |
| 5–8 | 50 | 5 mg | 0.50 mL | Inject 50 units (5 mg) subcutaneously once weekly. |
| 9–12 | 75 | 7.5 mg | 0.75 mL | Inject 75 units (7.5 mg) subcutaneously once weekly. |
| 13–16 | 100 | 10 mg | 1.0 mL | Inject 100 units (10 mg) subcutaneously once weekly. |
| 17–20 | 37.5 | 12.5 mg | 0.37 mL | Inject 37.5 units (12.5 mg) subcutaneously once weekly. |
| 21+ | 50 | 15 mg | 0.5 mL | Inject 50 units (15 mg) subcutaneously once weekly. |
FAQ
Frequently asked questions
Provider workflow
Ready to prescribe Tirzepatide?
Submit a prescription through the Logos RX provider portal, or reach out to our pharmacy team for formulary, dosing, or patient-onboarding questions.
Tirzepatide
Provider onboarding portal